Цефтазидим-MIP

Основна информация

  • Търговско наименование:
  • Цефтазидим-MIP 2 g прах за инжекционен/инф.разтвор x 1; x 5; x 10
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици

Документи

Локализация

  • Предлага се в:
  • Цефтазидим-MIP 2 g прах за инжекционен/инф.разтвор x 1; x 5; x 10
    България
  • Език:
  • български

Терапевтична информация

  • Каталог на резюме:
  • Ceftazidim-MIP, 2 g powder for solution for injection/infusion x 1; x 5; x 10 vials

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Номер на разрешението:
  • 20150171
  • Дата Оторизация:
  • 26-05-2015
  • Последна актуализация:
  • 01-06-2018

Листовка за пациента

28-9-2018

FDA approves first treatment for advanced form of the second most common skin cancer

FDA approves first treatment for advanced form of the second most common skin cancer

FDA approves Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

FDA - U.S. Food and Drug Administration

9-9-2011

Danish Pharmacovigilance Update, 18 August 2011

Danish Pharmacovigilance Update, 18 August 2011

Among the topics covered in this issue are Vimpat® 15mg/ml syrup (lacosamide) for treatment of epilepsy, which is recalled due to a quality defect and Nplate® (romiplostim), which could increase the risk of disease progression in patients with myelodysplastic syndrome (MDS).

Danish Medicines Agency

15-5-2018

Pramipexole Accord (Accord Healthcare Limited)

Pramipexole Accord (Accord Healthcare Limited)

Pramipexole Accord (Active substance: pramipexole) - Centralised - Yearly update - Commission Decision (2018)2995 of Tue, 15 May 2018

Europe -DG Health and Food Safety

3-5-2018

Pramipexole Teva (Teva B.V.)

Pramipexole Teva (Teva B.V.)

Pramipexole Teva (Active substance: pramipexole) - Centralised - Yearly update - Commission Decision (2018)2775 of Thu, 03 May 2018

Europe -DG Health and Food Safety

2-2-2018

MiPet Easecto (Zoetis Belgium S.A.)

MiPet Easecto (Zoetis Belgium S.A.)

MiPet Easecto (Active substance: sarolaner) - New authorisation - Commission Decision (2018)656 of Fri, 02 Feb 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4732

Europe -DG Health and Food Safety

10-11-2017

Pending EC decision:  Nplate, romiplostim, Opinion date: 09-Nov-2017

Pending EC decision: Nplate, romiplostim, Opinion date: 09-Nov-2017

Europe - EMA - European Medicines Agency